

Efficacy and Safety of Asparaginase-containing Treatment Regimens in ALL/LBL and Beyond

INTERACTIVE REVIEW FOR ONCOLOGY NURSES AND NURSE PRACTITIONERS

Presented by Creative Educational Concepts, LLC. Supported by an educational grant from Jazz Pharmaceuticals.





Sandra Kurtin
PhD, ANP-BC, FAPO

Director, Advanced Practice,
Nurse Practitioner

The University of Arizona Cancer Center
Assistant Professor of Clinical Medicine
Adjunct Clinical Professor of Nursing
The University of Arizona

Agenda



- 5 minutes** Welcome and Introductions/Pre-test
- 10 minutes** The Role of Asparaginase: Mechanism in ALL/LBL and Other Disease States
- 20 minutes** Bolstering Confidence in the Use of Asparaginase-Containing Treatment Regimens: A Data-Driven Discussion for Optimal Management
- 15 minutes** Zeroing in On Safety and Defining the Difference: Infusion Reactions, Hypersensitivity, and Monitoring in Clinical Practice
- 10 minutes** Conversations with the Expert/Audience Q&A/Post-test

Faculty Disclosures



It is the policy of Creative Educational Concepts LLC (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers' bureaus, other benefits, or having a self-managed equity interest in a company. CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planner/Faculty

Sandra Kurtin, PhD, ANP-C, AOCN—has disclosed that she is an advisor or consultant to Abbvie, Agios, Amgen, AstraZeneca, Bristol Myers Squibb, Incyte, and Takeda.

Peer Reviewer

Stacy Muddiman, BSN, RN, OCN—has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff

Katherine Lee, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Jessica Hall—has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Thank You



Presented by Creative Educational Concepts



*Supported through an independent educational grant from Jazz
Pharmaceuticals*

Learning Objectives



1. Examine the rationale for using asparaginase in the treatment of pediatric and adult/young adult acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL), as well as in other disease states.
2. Appraise key clinical trial data of different asparaginase-containing regimens in ALL/LBL and apply that knowledge to selection of optimal asparaginase-containing treatments, based on patient-specific factors as well as the latest data.
3. Identify the different asparaginase products available, and distinguish them based upon dose, route, formulation, proper monitoring, PK profiles, and unique safety concerns.
4. Recognize asparaginase-related toxicities that lead to poorer patient prognosis, identify the difference between asparaginase infusion reactions and clinical/subclinical hypersensitivity, develop monitoring/interpretation strategies for serum asparaginase levels to optimize treatment, and understand silent inactivation.
5. Use a case-based approach to formulate clinical strategies for asparaginase-containing regimens, focusing on efficacy and safety of different formulations, and practice approaches to monitor asparaginase levels while also preventing and mitigating asparaginase-related toxicities.

Accreditation



Nurses: 1.0 ANCC contact hour:

<https://www.surveymonkey.com/r/QYV5VBG>




E-Syllabus



An electronic version of the handout and program resources are available for download at:

<https://www.ceconcepts.com/sites/default/files/course/2022-12/179--JAZZ22ALLONS--HANDOUT.pdf>





Efficacy and Safety of Asparaginase-containing Treatment Regimens in ALL/LBL and Beyond

INTERACTIVE REVIEW FOR ONCOLOGY NURSES AND NURSE PRACTITIONERS

Presented by Creative Educational Concepts, LLC. Supported by an educational grant from Jazz Pharmaceuticals.

